IL224371A - 1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment - Google Patents

1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment

Info

Publication number
IL224371A
IL224371A IL224371A IL22437113A IL224371A IL 224371 A IL224371 A IL 224371A IL 224371 A IL224371 A IL 224371A IL 22437113 A IL22437113 A IL 22437113A IL 224371 A IL224371 A IL 224371A
Authority
IL
Israel
Prior art keywords
treatment
compound
patient
weight
disease
Prior art date
Application number
IL224371A
Other languages
English (en)
Hebrew (he)
Original Assignee
H Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL224371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck A/S filed Critical H Lundbeck A/S
Publication of IL224371A publication Critical patent/IL224371A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL224371A 2010-08-23 2011-08-22 1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment IL224371A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
IL224371A true IL224371A (en) 2016-07-31

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
IL224371A IL224371A (en) 2010-08-23 2011-08-22 1– [2– (2,4-dimethyl-phenylsulfanyl) phenyl] piperazine for disease treatment

Country Status (32)

Country Link
US (5) US20130184291A1 (enExample)
EP (1) EP2608789B2 (enExample)
JP (1) JP5902169B2 (enExample)
KR (1) KR101816953B1 (enExample)
CN (1) CN103068389A (enExample)
AP (1) AP3583A (enExample)
AR (1) AR082501A1 (enExample)
AU (1) AU2011295465B8 (enExample)
BR (2) BR112013002194A2 (enExample)
CA (1) CA2807062C (enExample)
CL (1) CL2013000492A1 (enExample)
CO (1) CO6680652A2 (enExample)
CY (1) CY1118886T1 (enExample)
DK (1) DK2608789T4 (enExample)
ES (1) ES2625142T5 (enExample)
FI (1) FI2608789T4 (enExample)
HR (1) HRP20170608T4 (enExample)
HU (1) HUE034155T2 (enExample)
IL (1) IL224371A (enExample)
LT (1) LT2608789T (enExample)
ME (1) ME02674B (enExample)
MX (1) MX349724B (enExample)
PL (1) PL2608789T5 (enExample)
PT (1) PT2608789T (enExample)
RS (1) RS55851B2 (enExample)
RU (1) RU2564666C2 (enExample)
SG (1) SG187649A1 (enExample)
SI (1) SI2608789T2 (enExample)
SM (1) SMT201700239T1 (enExample)
TW (1) TW201212918A (enExample)
WO (1) WO2012025123A1 (enExample)
ZA (1) ZA201301385B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DK0543584T3 (da) * 1991-11-18 1996-07-01 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamider til behandling af forstyrrelser i centralnervesystemet
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7159383B2 (en) 2000-10-02 2007-01-09 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
BR122020011920A2 (pt) 2006-06-16 2020-08-25 Lundbeck & Co As H composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
FI2608789T4 (fi) 2024-11-01
US20220370439A1 (en) 2022-11-24
CA2807062A1 (en) 2012-03-01
EP2608789A1 (en) 2013-07-03
US20190000836A1 (en) 2019-01-03
AP2013006768A0 (en) 2012-03-31
BR112013002194A2 (pt) 2016-05-31
SG187649A1 (en) 2013-03-28
KR101816953B1 (ko) 2018-01-09
CN103068389A (zh) 2013-04-24
SMT201700239T1 (it) 2017-07-18
MX349724B (es) 2017-08-10
AU2011295465B2 (en) 2014-06-19
MX2013001570A (es) 2013-03-21
EP2608789B1 (en) 2017-04-12
CL2013000492A1 (es) 2013-06-07
KR20130097162A (ko) 2013-09-02
AU2011295465A1 (en) 2013-02-07
EP2608789B2 (en) 2024-08-21
ME02674B (me) 2017-06-20
RS55851B1 (sr) 2017-08-31
PT2608789T (pt) 2017-05-26
HRP20170608T4 (hr) 2024-12-06
AU2011295465B8 (en) 2014-07-10
JP2013536206A (ja) 2013-09-19
TW201212918A (en) 2012-04-01
ZA201301385B (en) 2014-04-30
HUE034155T2 (en) 2018-01-29
JP5902169B2 (ja) 2016-04-13
SI2608789T2 (sl) 2025-05-30
RS55851B2 (sr) 2024-11-29
AP3583A (en) 2016-02-09
RU2013112890A (ru) 2014-09-27
HRP20170608T1 (hr) 2017-07-28
PL2608789T3 (pl) 2017-09-29
BR122020025600A2 (pt) 2021-01-05
CY1118886T1 (el) 2018-01-10
SI2608789T1 (sl) 2017-06-30
CA2807062C (en) 2018-07-31
ES2625142T5 (en) 2025-02-10
RU2564666C2 (ru) 2015-10-10
LT2608789T (lt) 2017-05-25
CO6680652A2 (es) 2013-05-31
US20130184291A1 (en) 2013-07-18
ES2625142T3 (es) 2017-07-18
AR082501A1 (es) 2012-12-12
US20210085674A1 (en) 2021-03-25
US20240293397A1 (en) 2024-09-05
DK2608789T3 (en) 2017-05-15
DK2608789T4 (da) 2024-11-04
WO2012025123A1 (en) 2012-03-01
PL2608789T5 (pl) 2025-11-12

Similar Documents

Publication Publication Date Title
US20240293397A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
Outfitters et al. Revisiting monoamine oxidase inhibitors
Wellington et al. Venlafaxine extended-release: a review of its use in the management of major depression
US20020099045A1 (en) Combination treatment for depression
JP2004517112A (ja) 新規薬物コンビネーション
EP2523557B1 (en) Methods of providing weight loss therapy in patients with major depression
TW202317101A (zh) 治療抑鬱狀態之方法
EP0759299A1 (en) Potentiation of serotonin response
HK1184374A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
EP4262769A1 (en) Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
US20030212109A1 (en) Pharmaceutical compositions and their use
WO2023036820A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20140069120A (ko) S1p 수용체 조절제를 포함하는 조합물
US20050107466A1 (en) Method of treating or reducing suicidal thoughts with escitalopram
JPWO2007034910A1 (ja) 過食症及び過食症に伴ううつ病の治療用医薬組成物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed